Case Reports
doi: 10.1097/MJT.0000000000001681.
Immune-Mediated Diabetes Mellitus, Diabetic Ketoacidosis, Enteritis, and Thrombotic Thrombocytopenic Purpura Presenting as Adverse Effects of Pembrolizumab Therapy
Affiliations
- PMID: 38976534
- DOI: 10.1097/MJT.0000000000001681
Item in Clipboard
Case Reports
Immune-Mediated Diabetes Mellitus, Diabetic Ketoacidosis, Enteritis, and Thrombotic Thrombocytopenic Purpura Presenting as Adverse Effects of Pembrolizumab Therapy
Am J Ther.
2024 Jul-Aug.
No abstract available
Conflict of interest statement
The authors have no conflicts of interest to declare.
Similar articles
-
Pembrolizumab-induced thrombotic thrombocytopenic purpura.J Oncol Pharm Pract. 2020 Jul;26(5):1237-1240. doi: 10.1177/1078155219887212. Epub 2019 Nov 13. J Oncol Pharm Pract. 2020. PMID: 31718453
-
Diabetic ketoacidosis following immunotherapy for lung cancer.Tidsskr Nor Laegeforen. 2019 Feb 25;139(4). doi: 10.4045/tidsskr.18.0597. Print 2019 Feb 26. Tidsskr Nor Laegeforen. 2019. PMID: 30808100 English, Norwegian. No abstract available.
-
Diabetic ketoacidosis induced by a single dose of pembrolizumab.Am J Emerg Med. 2019 Feb;37(2):376.e1-376.e2. doi: 10.1016/j.ajem.2018.10.040. Epub 2018 Oct 21. Am J Emerg Med. 2019. PMID: 30361152
-
Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.Front Endocrinol (Lausanne). 2020 Jan 28;11:14. doi: 10.3389/fendo.2020.00014. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32047478 Free PMC article. Review.
-
Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.J Clin Endocrinol Metab. 2018 Sep 1;103(9):3144-3154. doi: 10.1210/jc.2018-00728. J Clin Endocrinol Metab. 2018. PMID: 29955867 Review.
References
-
- Wu L, Li B. A case of severe diabetic ketoacidosis associated with pembrolizumab therapy in a patient with metastatic melanoma. Diabetes Metab Syndr Obes Targets Ther. 2021;14:753–757.
-
- Cheema A, Makadia B, Karwadia T, et al. Autoimmune diabetes associated with pembrolizumab: a review of published case reports. World J Oncol. 2018;9:1–4.
-
- Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J ImmunoTherapy Cancer. 2015;3:36.
-
- Hayata M, Shimanuki M, Ko T, et al. Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review. Ren Replace Ther. 2020;6:29.
-
- Sankar K, Macfarlane M, Cooper O, et al. Pembrolizumab-induced diabetic ketoacidosis: a review of critical Care case. Cureus. 2021;13:e18983.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical